BiotechTube

GWP42003 + GWP42003 + GWP42004 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemias

Conditions

Dyslipidemias, Diabetes Mellitus, Type 2

Trial Timeline

Oct 1, 2010 → Sep 1, 2012

NCT ID
NCT01217112

About GWP42003 + GWP42003 + GWP42004 + Placebo

GWP42003 + GWP42003 + GWP42004 + Placebo is a phase 2 stage product being developed by Jazz Pharmaceuticals for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT01217112. Target conditions include Dyslipidemias, Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01217112Phase 2Completed

Competing Products

15 competing products in Dyslipidemias

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
33
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
85
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
33
LY3885125 + PlaceboEli LillyPhase 1
33
LY3561774 + PlaceboEli LillyPhase 1
33
LY3561774 + PlaceboEli LillyPhase 2
52
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
52
Atorvastatin + AtorvastatinPfizerApproved
84
AtorvastatinPfizerApproved
84
Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved
84
Vupanorsen + PlaceboPfizerPhase 2
51
AtorvastatinPfizerApproved
84
Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved
84
ARO-APOC3Arrowhead PharmaceuticalsPhase 2
49
ARO-ANG3 + sterile normal saline (0.9% NaCl)Arrowhead PharmaceuticalsPhase 1
30

Other Products from Jazz Pharmaceuticals

Sativex + PlaceboApproved
82
Sodium OxybateApproved
82
JZP258Approved
82
Solriamfetol + PlaceboApproved
82
Placebo + Sodium OxybateApproved
82